Genzyme/Bayer Get FDA Approval For Campath As First-Line Treatment In Lymphocytic Leukemia
Bayer, who markets the mAb, does not plan any expansion of its 90-strong U.S. sales force in light of the label extension, firm tells “The Pink Sheet” DAILY.
Bayer, who markets the mAb, does not plan any expansion of its 90-strong U.S. sales force in light of the label extension, firm tells “The Pink Sheet” DAILY.